


Listing of claims

Claims:

1. (Currently amended) A method for treating a skin microcirculatory disorder (SMD) comprising topically administering ~~The use of~~ a hydroxypyridonone of formulae (I-III):



wherein

R¹ represents a (C₁-C₁₀)- alkyl, (C₁-C₁₀)-alkenyl, (C₁-C₁₀)-alkoxy, (C₁-C₁₀) hydroxyalkyl, (C₅-C₁₂) -aralkyl, (C₃-C₁₂)-cycloalkyl, (C₁-C₈)- carboalkoxy or (C₁-C₈)- carbamyl, or a (C₁₀-C₃₀)-peptide or peptidomimetic moiety, or a (C₃-C₆) polyol or monosaccharide;

R² represents an hydrogen atom or a linear or branched, saturated or unsaturated lo (C₁-C₂₂)-acyl, optionally substituted by (C₁-C₈)-alkoxy, carboxy, (C₁-C₈) alkoxy carbonyl, amino, hydroxy, said amino and hydroxy being optionally (C₁-C₂₂)-acylated or - alkylated;

R³, R⁴ and R⁵, each individually, represent a hydrogen atom, or (C₁-C₁₀)-alkyl, (C₁-C₁₀)- alkenyl, (C₁-C₁₀)-alkoxy, (C₅-C₁₂ aryl) alkyl, (C₅-C₁₂)-cycloalkyl, (C₁-C₈ carbo)-alkoxy or (C₁-C₈)-carbamyl group;

with the proviso that both R¹ and R³ are not hydrogen;

~~and/or a dermatologically/cosmetically saltssalt thereof. for the manufacture of a topical medicament useful in the treatment of a skin microcirculatory disorder (SMD).~~

2. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is rosacea.

3. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is cutaneous vasculitis.

4. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is actinic purpura.

5. (Currently amended) A method Use according to claim 1, wherein the MSD skin microcirculatory disorder (SMD) is a skin capillaritis.

6. (Currently amended) A method Use- according to claim 8, wherein the skin capillaritis is ~~selected in the group consisting of~~ progressive pigmentary dermatosis, purpura annularis telangiectodes, lichen aureus, contact allergy skin capillaritis, ~~and~~ lichens aureus, itching purpura, eczematid-like purpura, ~~and or~~ pigmented purpuric lichenoid dermatosis.


7. (Currently amended) A method Use- according to claim 1, wherein the ~~MSD skin~~ microcirculatory disorder (SMD) is a consequence of a traumatic intradermal haemorrhage ~~selected in the group consisting of that is a~~ drug-induced pigmented purpuric dermatosis ~~and or~~ a complication of sclerotherapy, lipoplasty ~~and or~~ tattooing.

8. (Currently amended) A method Use- according to claim 1, wherein R^1 and R^2 are methyl, R^3 and R^4 are hydrogens.

9. (Currently amended) A method Use- according to claim 1, wherein R^1 and R^2 are ethyl R^3 and R^4 are hydrogens.

10. (Currently amended) A method Use- according to claim 1, wherein ~~Rat~~ R^1 is CH_2CH_2OH , R^2 is methyl or ethyl, and R^3 and R^4 are hydrogens.

11. (Currently amended) A method for the treatment of skin microcirculatory disorder (SMD) comprising the ~~local application~~ locally applying to a mammal in need thereof of a therapeutically effective amount of hydroxypyridonone compound according to ~~claim 1~~ of formulae (I-III):



wherein

R^1 represents a (C_1-C_{10}) - alkyl, (C_1-C_{10}) -alkenyl, (C_1-C_{10}) -alkoxy, (C_1-C_{10}) hydroxyalkyl, (C_5-C_{12}) -aryl, (C_3-C_{12}) -cycloalkyl, (C_1-C_8) - carboalkoxy or (C_1-C_8) - carbamyl, or a $(C_{10}-C_{30})$ -peptide or peptidomimetic moiety, or a (C_3-C_6) polyol or monosaccharide;

R^2 represents an hydrogen atom or a linear or branched, saturated or unsaturated (C_1-C_{22}) -acyl, optionally substituted by (C_1-C_8) -alkoxy, carboxy, (C_1-C_8) alkoxycarbonyl, amino, hydroxy, said amino and hydroxy being optionally (C_1-C_{22}) -acylated or - alkylated;

R^3 , R^4 and R^5 , each individually, represent a hydrogen atom, or (C_1-C_{10}) -alkyl, (C_1-C_{10}) - alkenyl, (C_1-C_{10}) -alkoxy, (C_5-C_{12}) aryl alkyl, (C_5-C_{12}) -cycloalkyl, (C_1-C_8) carbo)-alkoxy or (C_1-C_8) -carbamyl group;

with the proviso that both R^1 and R^3 are not hydrogen;

~~and~~ or a dermatologically/cosmetically acceptable salt thereof

in admixture with a dermatologically/cosmetically acceptable ~~ingredients and carriers~~ carrier.

12. (Currently amended) A method ~~Method~~ according to claim 11, for the treatment of rosacea, cutaneous vasculitis, ~~and~~ or actinic purpura.

13. (Currently amended) A method ~~Method~~ according to claim 14, for the treatment of progressive pigmented purpura, itching purpura, pigmented purpuric lichenoid dermatosis, purpura annularis telangiectodes, contact allergy skin capillaritis, ~~and~~ or lichens aureus.

14. (Currently amended) A method ~~Method~~ according to claim 14, for the treatment of traumatic skin haemorrhage, a complication of sclerotherapy, lipoplasty or tattooing, drug-induced pigmented purpuric dermatosis, ~~and~~ or actinic purpura.

15. (New) A method according to claim 11, wherein R^2 , R^3 , R^4 and R^5 , each individually, represent a hydrogen atom.

16. (New) A method according to claim 11, wherein R^1 and R^3 each individually, represent (C_1 - C_4)- alkyl, hydroxyalkyl or alkoxy.

17. (New) A method according to claim 11, wherein said R^2 acyl group is formed by unbranched, naturally occurring caprylic acid, cupric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic, linoleic acid, alpha-linolenic acid, eleostearic, delta-linolenic acid, gondoic acid, dihomo- γ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docosenoic acid, docosatekaenoic acid, docosapentaenoic acid, docosapentaenoic, docosahexaenoic acid, nervonic or a mixture thereof.

18. (New) A method according to claim 11, wherein said R^2 acyl is a C_{1-8} which is branched at the carbon atom adjacent to the carbonyl group.

19. (New) A method according to claim 11, wherein said hydroxypyridonone is 1, 2 dimethyl-3-hydroxy-4-pyridinone (deferiprone); 1,2-diethyl-3- hydroxy- 4-pyridinone; 1-methyl-2-ethyl-3-hydroxy-4-pyridinone; 1-methyl- 2-ethyl-3-hydroxy-4 pyridinone or 1-methyl-2-(2-methoxy-ethyl)-3-hydroxy-4- pyridinone.